TY - JOUR
T1 - Salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin's lymphoma with a combination of dexamethasone, etoposide, ifosfamide and carboplatin
AU - Okamoto, M.
AU - Maruyama, F.
AU - Tsuzuki, M.
AU - Nomura, T.
AU - Miyazaki, H.
AU - Wakita, M.
AU - Kojima, H.
AU - Sobue, R.
AU - Matsui, T.
AU - Ino, T.
N1 - Copyright:
This record is sourced from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
PY - 1994/7
Y1 - 1994/7
N2 - Seventeen patients with refractory or relapsed, intermediate or high grade non-Hodgkin's lymphoma (NHL) were treated with the combination of dexamethasone (40 mg/body x 3d, iv) (DeVIC) between January and December 1992. The treatments were repeated every three weeks for a minimum of two courses unless the patient had PD. G-CSF (2 micrograms/kg, sc) was given during leukopenia in most cases. Of 16 evaluable patients 6 (38%) achieved a complete remission (CR) and 4 showed a partial remission. With median follow up of 15 (7-26) months (mos.) all CR patients were alive in CR, except for 1 patient who died of secondary AML. The actuarial 50% survival duration after DeVIC was 15+ mos. One patient died of sepsis but myelosuppression was generally moderate and no other serious toxicity was observed. Although this is a preliminary study, DeVIC regimen seems to be an effective salvage therapy for patients with refractory or relapsed NHL with acceptable toxicity.
AB - Seventeen patients with refractory or relapsed, intermediate or high grade non-Hodgkin's lymphoma (NHL) were treated with the combination of dexamethasone (40 mg/body x 3d, iv) (DeVIC) between January and December 1992. The treatments were repeated every three weeks for a minimum of two courses unless the patient had PD. G-CSF (2 micrograms/kg, sc) was given during leukopenia in most cases. Of 16 evaluable patients 6 (38%) achieved a complete remission (CR) and 4 showed a partial remission. With median follow up of 15 (7-26) months (mos.) all CR patients were alive in CR, except for 1 patient who died of secondary AML. The actuarial 50% survival duration after DeVIC was 15+ mos. One patient died of sepsis but myelosuppression was generally moderate and no other serious toxicity was observed. Although this is a preliminary study, DeVIC regimen seems to be an effective salvage therapy for patients with refractory or relapsed NHL with acceptable toxicity.
UR - http://www.scopus.com/inward/record.url?scp=0028469621&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028469621&partnerID=8YFLogxK
M3 - Article
C2 - 8065017
AN - SCOPUS:0028469621
VL - 35
SP - 635
EP - 641
JO - [Rinsho ketsueki] The Japanese journal of clinical hematology
JF - [Rinsho ketsueki] The Japanese journal of clinical hematology
SN - 0485-1439
IS - 7
ER -